Posted: 19 April 2023
Amplia Therapeutics Limited is pleased to advise that dosing of the first patient in Cohort 3 of the Company’s ongoing Phase 1b/2a ACCENT clinical trial of FAK inhibitor AMP945 in pancreatic cancer has begun.
Cohort 3 will consist of three patients receiving an increased dose of AMP945 after the safety committee’s recent assessment that the AMP945 dose used in Cohort 2 was safe and well-tolerated. In the ACCENT trial, AMP945 is dosed orally (as a capsule) in the lead-up to, and between, standardised weekly dosing of gemcitabine and nab-paclitaxel chemotherapy.
Amplia CEO and Managing Director, Dr Chris Burns, commented: “We are very pleased with the recent progress in the ACCENT trial and moving rapidly to Cohort 3 is the next step in identifying a safe and effective dose to take forward to the Phase 2 stage of the trial. We are extremely grateful to the clinical trial sites for their hard work in progressing the trial so quickly, and to the patients and their loved ones for agreeing to take part in this trial.”
